Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 16/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.47 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20137142 | 0.89 | MGLL (0.72) | MGLLCYP2D6ABHD6PLA2G7 | |
| SCHEMBL19628035 | 0.85 | MGLL (0.54) | MGLLCYP2D6TSHRABHD6PLA2G7 | |
| SCHEMBL20151771 | 0.82 | MGLL (0.63) | MGLLCYP2D6TSHRABHD6PLA2G7 | |
| SCHEMBL19386375 | 0.81 | MGLL (0.48) | MGLLCYP2D6TSHRABHD6PLA2G7 | |
| SCHEMBL19386382 | 0.81 | MGLL (0.49) | MGLLCYP2D6TSHRABHD6PLA2G7 | |
| SCHEMBL19628040 | 0.81 | MGLL (0.56) | MGLLCYP2D6TSHRABHD6PLA2G7 | |
| SCHEMBL20151795 | 0.81 | MGLL (0.83) | MGLLCYP2D6TSHR | |
| SCHEMBL20151783 | 0.81 | MGLL (0.85) | MGLLCYP2D6TSHRABHD6PLA2G7 | |
| SCHEMBL19628037 | 0.80 | MGLL (0.49) | MGLLCYP2D6TSHRABHD6PLA2G7 | |
| SCHEMBL16744452 | 0.79 | MGLL (0.60) | MGLLABHD6PLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134674-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | MGLL 3/4885CYP2D6 3916/4885TSHR 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.